RXi Takes License to Self-Delivering RNAi Agents, Ends RNAi Tech-License Deals with UMMS | GenomeWeb

By Doug Macron

RXi Pharmaceuticals this week announced that it has exercised an option to acquire technology related to self-delivering RNAi molecules from Advirna, a Boulder, Colo.-based biotech firm co-founded by RXi's chief scientific officer.

Separately this week, the company disclosed that it has terminated six of its licensing agreements with the University of Massachusetts Medical School, as well as an invention-disclosure agreement, while amending its license to an oral RNAi drug-delivery technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.